OBJECTIVE: Peptidylarginine deiminase 4 (PAD4) is a citrullinating enzyme that has multiple associations with inflammation. In rheumatoid arthritis, PAD4 and protein citrullination are increased in inflamed joints, and anti-citrullinated protein antibodies (ACPAs) form against citrullinated antigens are formed. ACPA immune complexes can deposit in the joint and induce the production of tumor necrosis factor α (TNFα), a critical inflammatory cytokine in the pathogenesis of rheumatoid arthritis. Further, in other settings, TNFα has been shown to induce PAD4 activity and modulate antibody formation. We undertook this study to investigate whether TNFα and PAD4 may synergistically exacerbate autoantibody production and inflammatory arthritis. METHODS: To determine whether TNFα and PAD4 augment autoantibody production and inflammatory arthritis, we first used a multiplex assay to determine whether mice with chronic inflammatory arthritis due to overexpression of TNFα develop autoantibodies against native and citrullinated antigens. With TNF(+) PAD4(+/+) and TNF(+) PAD4(-/-) mice, we then compared serum autoantibody levels by multiplex array, lymphocyte activation by flow cytometry, total serum IgG levels by enzyme-linked immunosorbent assay, arthritis by clinical and histologic scoring, and systemic inflammation using microfluidic devices. RESULTS: TNFα-overexpressing mice had increased levels of autoantibodies reactive against native and citrullinated antigens. PAD4(-/-) mice with TNFα-induced arthritis had lower levels of autoantibodies reactive against native and citrullinated antigens, decreased T cell activation and total IgG levels, and reduced inflammation and arthritis compared to PAD4(+/+) TNFα-overexpressing mice. CONCLUSION: PAD4 mediates autoantibody production and inflammatory arthritis downstream of TNFα.
OBJECTIVE: Peptidylarginine deiminase 4 (PAD4) is a citrullinating enzyme that has multiple associations with inflammation. In rheumatoid arthritis, PAD4 and protein citrullination are increased in inflamed joints, and anti-citrullinated protein antibodies (ACPAs) form against citrullinated antigens are formed. ACPA immune complexes can deposit in the joint and induce the production of tumor necrosis factor α (TNFα), a critical inflammatory cytokine in the pathogenesis of rheumatoid arthritis. Further, in other settings, TNFα has been shown to induce PAD4 activity and modulate antibody formation. We undertook this study to investigate whether TNFα and PAD4 may synergistically exacerbate autoantibody production and inflammatory arthritis. METHODS: To determine whether TNFα and PAD4 augment autoantibody production and inflammatory arthritis, we first used a multiplex assay to determine whether mice with chronic inflammatory arthritis due to overexpression of TNFα develop autoantibodies against native and citrullinated antigens. With TNF(+) PAD4(+/+) and TNF(+) PAD4(-/-) mice, we then compared serum autoantibody levels by multiplex array, lymphocyte activation by flow cytometry, total serum IgG levels by enzyme-linked immunosorbent assay, arthritis by clinical and histologic scoring, and systemic inflammation using microfluidic devices. RESULTS:TNFα-overexpressing mice had increased levels of autoantibodies reactive against native and citrullinated antigens. PAD4(-/-) mice with TNFα-induced arthritis had lower levels of autoantibodies reactive against native and citrullinated antigens, decreased T cell activation and total IgG levels, and reduced inflammation and arthritis compared to PAD4(+/+) TNFα-overexpressing mice. CONCLUSION:PAD4 mediates autoantibody production and inflammatory arthritis downstream of TNFα.
Authors: Justin E Jones; Jessica L Slack; Pengfei Fang; Xuesen Zhang; Venkataraman Subramanian; Corey P Causey; Scott A Coonrod; Min Guo; Paul R Thompson Journal: ACS Chem Biol Date: 2011-10-21 Impact factor: 5.100
Authors: Alexander A Chumanevich; Corey P Causey; Bryan A Knuckley; Justin E Jones; Deepak Poudyal; Alena P Chumanevich; Tia Davis; Lydia E Matesic; Paul R Thompson; Lorne J Hofseth Journal: Am J Physiol Gastrointest Liver Physiol Date: 2011-03-17 Impact factor: 4.052
Authors: G A Schellekens; B A de Jong; F H van den Hoogen; L B van de Putte; W J van Venrooij Journal: J Clin Invest Date: 1998-01-01 Impact factor: 14.808
Authors: E R Vossenaar; T R D Radstake; A van der Heijden; M A M van Mansum; C Dieteren; D-J de Rooij; P Barrera; A J W Zendman; W J van Venrooij Journal: Ann Rheum Dis Date: 2004-04 Impact factor: 19.103
Authors: Natacha Courvoisier; Maxime Dougados; Alain Cantagrel; Philippe Goupille; Olivier Meyer; Jean Sibilia; Jean Pierre Daures; Bernard Combe Journal: Arthritis Res Ther Date: 2008-09-04 Impact factor: 5.156
Authors: Richard D Bell; Emily K Wu; Christopher A Rudmann; Megan Forney; Claire R W Kaiser; Ronald W Wood; Joe V Chakkalakal; Nicole D Paris; Alanna Klose; Guang-Qian Xiao; Javier Rangel-Moreno; Maria L Garcia-Hernandez; Christopher T Ritchlin; Edward M Schwarz; Homaira Rahimi Journal: Arthritis Rheumatol Date: 2019-07-22 Impact factor: 10.995
Authors: Emily K Wu; Robert D Ambrosini; R Matthew Kottmann; Christopher T Ritchlin; Edward M Schwarz; Homaira Rahimi Journal: Curr Rheumatol Rev Date: 2019
Authors: Hongmei Li; Sang Jun Han; Mihwa Kim; Ahyeon Cho; Yewoon Choi; Vivette D'Agati; H Thomas Lee Journal: Am J Physiol Renal Physiol Date: 2018-01-03
Authors: V C Willis; N K Banda; K N Cordova; P E Chandra; W H Robinson; D C Cooper; D Lugo; G Mehta; S Taylor; P P Tak; R K Prinjha; H D Lewis; V M Holers Journal: Clin Exp Immunol Date: 2017-03-09 Impact factor: 4.330
Authors: Mandar Bawadekar; Daeun Shim; Chad J Johnson; Thomas F Warner; Ryan Rebernick; Dres Damgaard; Claus H Nielsen; Ger J M Pruijn; Jeniel E Nett; Miriam A Shelef Journal: J Autoimmun Date: 2017-02-07 Impact factor: 7.094
Authors: S F Moussavi-Harami; K M Mladinich; E K Sackmann; M A Shelef; T W Starnes; D J Guckenberger; A Huttenlocher; D J Beebe Journal: Integr Biol (Camb) Date: 2016-01-25 Impact factor: 2.192